BACKGROUND: Oral administration of the standardized Ginkgo biloba extract EGb 761ா has been shown to inhibit thermal hyperalgesia in rodent models of inflammatory and postsurgical pain, but the mechanism underlying these effects is not known. We sought to determine the site of action of EGb 761 by investigating the antihyperalgesic and antiinflammatory properties of EGb 761 after local and central drug administration in the rat carrageenan model of inflammation. METHODS: Adult male Wistar rats received an intraplantar injection of carrageenan (3%) or saline into the left hindpaw followed 3 hours later by an intraplantar injection of EGb 761 (30, 100, or 300 g) or vehicle into the left paw; or intrathecal injection of EGb 761 (0.5, 1, 3, 10, or 100 g) or vehicle into the lumbar spinal cord region. Diclofenac (100 g) was administered as a positive control. Hindpaw withdrawal latency (in seconds) to thermal stimulation, response threshold (in grams) to mechanical stimulation, and paw volume were measured at 0, 2, 4, 6, and 24 hours after carrageenan injection. RESULTS: Both intraplantar (30, 100, and 300 g) and intrathecal (0.5 and 1 g) EGb 761 significantly inhibited carrageenan-induced thermal hyperalgesia and were equally as effective as diclofenac, but had no effect on mechanical hypersenitivity. Application Ն3 g EGb 761 to the spinal cord induced adverse behavioral effects, which precluded further nociceptive testing. Intraplantar (300 g) and intrathecal (1 g) EGb 761 also significantly reduced paw edema. CONCLUSION: These studies show that EGb 761 acts both at the site of inflammation and centrally at the spinal cord level to inhibit inflammation and thermal hyperalgesia, and may be useful in the treatment of inflammatory pain.
G inkgo biloba extract EGb 761 is a standardized extract from the leaves of the ancient Ginkgo biloba tree and is known for its therapeutic effects on vascular and neurological function. 1, 2 Developed by Dr. Willmar Schwabe Pharmaceuticals since 1964, EGb 761 contains 24% flavonoids, 7% proanthocyanidins, 6% terpenoids, and Ͻ5 parts per million (ppm) ginkgolic acids and is prescribed in Germany and other countries for the treatment of dementia disorders. Compelling evidence suggests that Ginkgo biloba extract has analgesic and antiinflammatory properties. In this laboratory, oral administration of EGb 761 dose-dependently attenuated thermal hyperalgesia in a model of acute inflammatory pain induced by intradermal carrageenan, and after paw incision in rats. 3 Other reports have shown that Ginkgo biloba extract reduces capsaicin-induced hindpaw licking in rats, 4 attenuates mechanical and cold allodynia in a rat model of neuropathic pain, 5 and increases pain-free walking distance in patients with intermittent claudication. 6 There is also evidence for an antiinflammatory function of Ginkgo biloba extract, with reports that Ginkgo biloba inhibits formalin and carrageenan-induced paw edema 4 and reduces experimentally induced uveitis 7 in rats. These antiinflammatory properties are suggested to be mediated through inhibition of a range of proinflammatory mediators including nitric oxide (NO), interleukin-1␤ and tumor necrosis factor ␣ (TNF␣). [7] [8] [9] [10] [11] The mechanism underlying EGb 761's analgesic effects, however, remains to be identified. The aim of this study was to determine whether EGb 761's analgesic and antiinflammatory properties are mediated via activity at a peripheral site or a central site by investigating the therapeutic activity of the drug after local injection into the paw or intrathecal injection into the lumbar spinal cord region in a well-established rodent model of inflammation. The commonly prescribed nonsteriodal antiinflammatory drug, diclofenac, has been shown to inhibit carrageenan-induced hypersentivity in rats 12, 13 and was therefore included in this study as a positive control.
METHODS Animals
The study was approved by the Institute's Ethics and Welfare committee, and all procedures were performed according to the United Kingdom Animal Scientific Procedures Act (1986). Animals were treated in accordance with the Ethical Guidelines for Investigations of Experimental Pain in Conscious Animals, as issued by the International Association for the Study of Pain. Adult male Wistar rats (250 to 420 g) were used in these studies. Animals were bred in-house, kept from birth in pairs, and subjected to a light/dark cycle of 12 hours with water and food available ad libitum.
Experimental Protocol
Carrageenan (-carrageenan type IV; Sigma, Redhill, UK) was dissolved in saline to make a 3% solution 24 hours before the start of each study and stored at 4°C. Adult male Wistar rats received a 50-L intradermal injection of carrageenan (3%) into the left hindpaw, and responses to thermal and mechanical hindpaw stimulation and paw edema were measured before carrageenan injection (time 0) and 2, 4, 6, and 24 hours after carrageenan injection. EGb 761 (30, 100, or 300 g; n ϭ 6 rats per group; gift from Dr. Willmar Schwabe Pharmaceuticals, Karlsruhe, Germany) or vehicle (30% ethanol, 70% water; n ϭ 6) was injected intraplantarly in a total volume of 50 L 3 hours after carrageenan injection. Diclofenac (100 g; n ϭ 6; Sigma) was administered 3 hours after carrageenan injection as a positive control. A separate group of animals (n ϭ 3) received an intraplantar injection of saline, followed 3 hours later with an intraplantar injection of 30 g EGb 761 to investigate the effect of intrathecal on EGb 761 nociceptive thresholds in the absence of inflammation.
To investigate the central effects of the extract, we administered EGb 761 (0.5, 1, 3, 10, or 100 g; n ϭ 6 rats per group) or vehicle (15% ethanol, 85% water; n ϭ 6) intrathecally in a volume of 15 L 3 hours after carrageenan injection. Diclofenac (100 g; n ϭ 6; Sigma) was administered 3 hours after carrageenan injection as a positive control. For intrathecal injections, general anesthesia was induced by placing rats individually into a clear plexiglass induction chamber prefilled with 5% isoflurane (Isoflurane-Vet, Merial Animal Health Ltd., Harlow, UK) and O 2 (2 L/min; BOC, Guildford, UK) for approximately 10 minutes. Anesthesia was maintained with 2% isoflurane and O 2 (2 L/min) delivered via a nose cone. The site of injection was sterilized using a 10% povidone-iodine solution (National Veterinary Supplies, Stoke-on-Trent, UK). Intrathecal injections were made through L5 to 6 vertebrae using a 30-gauge needle. A separate group of animals (n ϭ 3) received an intraplantar injection of saline, followed 3 hours later with an intrathecal injection of 0.5 g EGb 761 to investigate the effect of intrathecal EGb 761, on nociceptive thresholds in the absence of inflammation.
Mechanical and Thermal Hypersensitivity and Paw Edema
One week before treatment, animals underwent acclimatization to the testing environment by placing them in the behavioral testing boxes for 30 to 60 minutes twice daily. During this period, animals were habituated to the testing devices. Baseline response thresholds to thermal or mechanical stimulation of both hindpaws were taken on 2 occasions the day before treatment and then at time 0 (immediately before carrageenan injection). A minimum of 3 readings was taken on each paw at each time point.
Animals were placed in an elevated transparent Perspex box and thermal hyperalgesia measured using the Ugo Basile Plantar Test (Hargreaves test), which directs an infrared beam onto the plantar surface of the hindpaw, until a withdrawal reflex (measured in seconds) is evoked. Mechanical hypersensitivity was assessed using a dynamic plantar aesthesiometer (Ugo Basile, Comerio, Italy). Animals were placed on an elevated wire-mesh-bottom cage and responses to punctate mechanical stimulation of the hindpaw assessed using the aesthesiometer (the force required to elicit withdrawal responses was measured in grams). Paw edema was measured using a plethsysmometer (Ugo Basile), which measures water displacement when the paw is submerged into a water cell and enables calculation of paw volume (in cubic centimeters). The volume of both paws was measured, and data were represented as the percentage difference in volume between the ipsilateral and contralateral paws.
Statistical Analysis
Data are represented as the mean Ϯ se of the mean (SEM). Threshold response data were analyzed using 2-way mixed factorial analysis of variance (ANOVA) (SPSS, version 12, Chicago, IL), where treatment is the between-subjects factor and time after carrageenan injection is the within-subjects (repeated measures) factor. Mean differences were calculated using simple effects analyses, applying Bonferroni adjustment factor for multiple comparisons. The maximum effect (E max : represented as a percentage according to the following formula: (maximal decrease in withdrawal threshold after treatment -baseline withdrawal threshold)/baseline withdrawal threshold ϫ 100) and time to maximum effect (T max ) were also calculated for each animal as the maximum change in withdrawal threshold (after carrageenan) from baseline responses and the time of measurement of the E max , respectively. These data were analyzed using a 1-way ANOVA with post hoc Tukey test (SPSS, version 12).
RESULTS

Peripheral Effects of EGb 761
Animals injected with carrageenan and treated intraplantarly with vehicle displayed significant thermal and mechanical hypersensitivity, and paw edema in the injected paw. No change in thermal or mechanical responses or paw edema was observed in the contralateral noninjected paw. A maximum decrease in thermal response latency of 50.4 Ϯ 4.3% was observed in the carrageenan-injected paw at 6 hours in animals treated with vehicle (P Ͻ 0.001 vs. precarrageenan response latencies). Intraplantar administration of EGb 761 (30, 100, and 300 g) significantly attenuated thermal hyperalgesia (P Ͻ 0.001 vs. vehicle; Fig.  1A ) with similar efficacy to diclofenac (P Ͻ 0.001 vs. vehicle; Fig. 1A ). EGb 761 and diclofenac had no effect on thermal response latencies in the contralateral paw. A maximum decrease in the mechanical response threshold of 51.1 Ϯ 7.6% was observed in the ipsilateral paw at 6 hours in animals treated with vehicle (P ϭ 0.002 vs. precarrageenan response thresholds). Intraplantar administration of EGb 761 and diclofenac had no effect on carrageenaninduced mechanical hypersensitivity (Fig. 1B) , nor on mechanical response thresholds in the contralateral paw.
Animals injected with carrageenan and treated with vehicle displayed significant edema in the ipsilateral paw 6 hours after carrageenan injection. The percentage difference in paw volume between the ipsilateral and contralateral hindpaws increased from a baseline value of -6.4 Ϯ 6.6% to 49.2 Ϯ 6.5% 6 hours after carrageenan injection (P ϭ 0.002 vs. precarrageenan values; Fig. 1C ). Intraplantar administration of 300 g EGb 761, but not 100 or 30 g EGb 761 or diclofenac, significantly reduced paw edema (P ϭ 0.037 vs. vehicle; Fig. 1C ). Intraplantar injection of 30 g EGb 761 had no effect on nociceptive responses or paw volume in control animals injected intradermally with saline (data not shown).
Central Effects of EGb 761
A pilot study was performed to determine a safe dose range for intrathecal EGb 761. The highest dose of EGb 761 tested (100 g; n ϭ 3 rats) resulted in the onset of severe adverse effects 10 to 12 minutes after recovery from anesthesia. These included vocalization, hyperextension, and muscle rigidity. Lower doses of 10 and 3 g EGb 761 (n ϭ 1 rat per dose) produced less severe but still pronounced adverse effects, including biting of hindquarters, abnormal gait, hunching, clubbing or crossing of the hindpaws, and rigidity of the hind region. Consequently, the intrathecal dose was reduced further to 1 g EGb 761, and no adverse effects were observed. Animals treated with vehicle recovered rapidly after brief general anesthesia, and there was no effect of anesthesia on nociceptive responses. After injection of carrageenan, a maximum decrease in thermal response latency of 56.1 Ϯ 4.9% was observed in the injected paw at 6 hours in animals treated intrathecally with vehicle (P ϭ 0.001 vs. precarrageenan response latencies). Intrathecal injection of EGb 761 (1 and 0.5 g) significantly attenuated thermal hyperalgesia (P ϭ 0.012 and P Ͻ 0.001, respectively, vs. vehicle; Fig. 2A ) with similar efficacy to intrathecal diclofenac (P ϭ 0.008 vs. vehicle). Intrathecal injection of EGb 761 or diclofenac had no effect on thermal response latencies in the contralateral paw. A maximum decrease in mechanical response threshold of 55.4 Ϯ 2.0% was observed in the ipsilateral paw at 6 hours in animals treated intrathecally with vehicle (P Ͻ 0.001 vs. precarrageenan response thresholds). Intrathecal administration of EGb 761 had no effect on carrageenan-induced mechanical hypersensitivity (Fig. 2B) . In contrast, diclofenac was found to significantly attenuate mechanical hypersensitivity (P ϭ 0.024 vs. vehicle; Fig. 2B ). Intrathecal administration of EGb 761 and diclofenac had no effect on mechanical response thresholds in the contralateral paw. Animals injected with carrageenan and treated intrathecally with vehicle displayed significant edema in the ipsilateral paw 6 hours after carrageenan injection. The percentage difference in paw volume between the ipsilateral and contralateral hindpaws increased from a baseline value of 5.1 Ϯ 3.8% to 45.4 Ϯ 2.8% 6 hours after carrageenan injection (P ϭ 0.001 vs. baseline values). Intrathecal administration of 1 g EGb 761 and diclofenac, but not 0.5 g EGb 761, significantly reduced paw edema (P ϭ 0.008 and P ϭ 0.05, respectively, vs. vehicle; Fig. 2C ). Intrathecal injection of 0.5 g EGb 761 had no effect on nociceptive responses or paw edema in control animals injected intradermally with saline ( Fig. 2 ).
DISCUSSION
The present study demonstrates that both peripheral and central administration of the standardized Ginkgo biloba extract EGb 761 blocks thermal hyperalgesia and paw edema but not mechanical hypersensitivity, induced by injection of carrageenan into the hindpaw in rats. The inhibition of thermal hyperalgesia by intraplantarly and intrathecally administered EGb 761 was comparable with the nonsteroidal antiinflammatory drug diclofenac. Previous studies in this laboratory have shown that systemically administered EGb 761 also selectively inhibited thermal hyperalgesia in response to carrageenan and paw incision, 3 but had no effect on mechanical hypersensitivity. These results indicate that EGb 761's antihyperalgesic activity is dependent on preferential inhibition of neuromodulators, receptors, or signaling molecules specific for thermal hyperalgesia. NO, a key mediator of nociceptive processing in the spinal cord, 14 is thought to be specifically involved in mediating thermal hyperalgesia. Intrathecal administration of the NO inhibitor N-nitro-l-arginine methyl ester reverses carrageenan-induced and nerve injury-induced thermal hyperalgesia but not mechanical allodynia, 15, 16 whereas administration of an NO donor, NOC-18, accelerates development of thermal hyperalgesia. 17 Previous studies in this laboratory have found that oral administration of EGb 761 prevents induction of inducible NO synthase mRNA in the spinal cord 6 hours after intradermal injection of carrageenan into the rat hindpaw (unpublished observations), suggesting that inhibition of the NO-signaling pathway may underlie the analgesic action of EGb 761. Other studies-showing that EGb 761 inhibits lipopolysaccharideinduced NO and inducible NO synthase in the mouse macrophage cell line, 9, 10 a human endothelial cell line, 8 and serum NO levels in mice 9 -support the theory that EGb 761 mediates its analgesic activity through inhibition of the NO signaling pathway.
The present results reveal that both peripheral and central administration of EGb 761 reduce carrageenaninduced paw edema, confirming previous reports that EGb 761 has significant antiinflammatory properties. Although previous studies in this laboratory failed to show a significant reduction in carrageenan-induced paw edema after oral administration of EGb 761, 3 other studies have shown that systemic administration of Ginkgo biloba extracts reduces paw edema in response to experimentally induced peripheral inflammation in rodents. 4, 18 Studies investigating antiinflammatory properties of flavanoids, quercetin, and kaempferol 3-O-sophoroside have also demonstrated reduced carrageenan-induced hindpaw edema in mice. 19, 20 The antiinflammatory action of locally administered EGb 761 is likely mediated through inhibition of release of inflammatory mediators, such as NO, prostaglandins, and proinflammatory cytokines into the paw tissue, because evidence shows that Gingko biloba and its constituents suppress induction of these mediators. [7] [8] [9] [10] 13, [21] [22] [23] Of interest is the inhibition of carrageenan-induced paw edema after spinal drug administration. Previous studies, such as the review by Waldburger and Firestein, 24 have reported that the spinal cord has modulatory control over peripheral inflammatory responses. Augmentation of peripheral inflammation is mediated through the dorsal root reflex, which involves antidromic signaling along afferent fibers, enhancing release of neuropeptides/neuromodulators at the site of inflammation and increasing vasodilation and neurogenic inflammation. 24 -26 Intrathecal injection of agents that modify prostaglandin production 27 -and glutamate, adenosine, and serotonin receptor signaling 28 -30 -have all been shown to reduce peripheral inflammation. A study by Boyle et al. 31 revealed that blocking p38 mitogen-activated protein kinase and tumor necrosis factor ␣ in the spinal cord reduces paw swelling, inhibits synovial inflammation, and decreases joint destruction in a rat adjuvant arthritis model, suggesting a role for proinflammatory cytokines in the spinal cord in regulating peripheral inflammation. Proinflammatory mediators-including cytokines, glutamate, and prostaglandins-are released in the spinal cord by activated glial cells in response to inflammation and tissue injury. 32 It is therefore hypothezied that inhibiting release of these proinflammatory mediators may underlie the antiinflammatory effects by EGb 761 at the spinal level.
Noteworthy are the results showing that intrathecal administration of higher doses of EGb 761 (3 to 100 g) produced adverse sensory and motor effects, including hindleg muscle rigidity, spasm, hyperextension, and vocalization, similar to those described after intrathecal administration of strychnine in rats. 33 The mechanism underlying EGb 761-induced adverse effects is not known but may be linked to blockade of inhibitory receptor signaling in the spinal cord, because the ginkgolides and bilobalide are known antagonists at both glycine and ␥-aminobutyric acid (GABA) A receptors. 34 -37 Indeed, recent studies in this laboratory have found strychnine-like side effects after intrathecal administration of bilobalide in rats (M. Goldie, unpublished observations). Bilobalide has also been shown to activate glycine binding sites on the N-methyl-daspartate receptor, a known target site for convulsants producing strychnine-like effects and for some EGb 761 constituents. 38 The proposed inhibition of glycine or GABA A receptor signaling in the spinal cord by EGb 761 is not consistent, however, with the antihyperalgesic effects of EGb 761 observed at lower doses, because disinhibition induced by blockade of glycine or GABA A receptors in the spinal cord induces touch-evoked hypersensitivity. 39 -41 Further studies are required to elucidate the mechanisms underlying EGb 761's therapeutic and adverse effects; however, the strychnine-like effects seen with higher doses make further intrathecal testing of this compound inappropriate in animal studies.
The present study demonstrates that both intraplantar and intrathecal administration of the Ginkgo biloba extract EGb 761 inhibits thermal hyperalgesia and paw edema induced by intradermal injection of carrageenan into the rat hindpaw, demonstrating that this compound has significant analgesic and antiinflammatory properties via activity at peripheral and central sites. These studies indicate that EGb 761 may offer therapeutic benefit for the treatment of postinjury-associated thermal hyperalgesia and acute inflammation.
